2020
Phenogenomic heterogeneity of post-transplant plasmablastic lymphomas
Leeman-Neill RJ, Soderquist CR, Montanari F, Raciti P, Park D, Radeski D, Mansukhani MM, Murty VV, Hsiao S, Alobeid B, Bhagat G. Phenogenomic heterogeneity of post-transplant plasmablastic lymphomas. Haematologica 2020, 107: 201-210. PMID: 33297669, PMCID: PMC8719101, DOI: 10.3324/haematol.2020.267294.Peer-Reviewed Original ResearchConceptsPlasmablastic lymphomaJAK/STATSolid organ allograft recipientsTargetable oncogenic pathwaysOrgan allograft recipientsAllograft recipientsComprehensive histopathologicEBV infectionHIV infectionPlasmablastic myelomaClinical outcomesClinicopathologic featuresYears postdiagnosisAggressive neoplasmDisease subsetsEBV- casesImmunophenotypic heterogeneityImmunophenotypic evaluationMAP kinaseImmunocompromised individualsMYC rearrangementDisease pathogenesisPhenotypic spectrumNotch pathway genesOncogenic pathways
2015
Recursive partitioning analysis of prognostic factors in post‐transplant lymphoproliferative disorders (PTLD): a 120 case single institution series
Montanari F, Radeski D, Seshan V, Alobeid B, Bhagat G, O'Connor OA. Recursive partitioning analysis of prognostic factors in post‐transplant lymphoproliferative disorders (PTLD): a 120 case single institution series. British Journal Of Haematology 2015, 171: 491-500. PMID: 26250758, DOI: 10.1111/bjh.13621.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedChildChild, PreschoolCombined Modality TherapyEpstein-Barr Virus InfectionsFemaleHumansImmunosuppressive AgentsInfantLymphoproliferative DisordersMaleMiddle AgedMultivariate AnalysisOrgan TransplantationPostoperative ComplicationsPrognosisRisk AssessmentRituximabSeverity of Illness IndexYoung AdultConceptsPost-transplant lymphoproliferative disorderECOG scoreElderly patientsPediatric patientsLymphoproliferative disordersEastern Cooperative Oncology Group scoreECOG score 0Setting of immunosuppressionDecade of diagnosisNew prognostic scoreSingle-institution seriesHigh-risk groupAdult patientsOverall survivalPrognostic factorsPrognostic scoreInstitution seriesSingle institutionScore 0Tissue allograftsPatientsLarge seriesRisk categoriesHeterogeneous groupRecursive partitioning model
2010
Bone marrow involvement in patients with posttransplant lymphoproliferative disorders: incidence and prognostic factors
Montanari F, O'Connor OA, Savage DG, Zain JM, Venkatraman S, McCormick EK, Crook MT, Tsao L, Sevilla DW, Bhagat G, Alobeid B. Bone marrow involvement in patients with posttransplant lymphoproliferative disorders: incidence and prognostic factors. Human Pathology 2010, 41: 1150-1158. PMID: 20381113, DOI: 10.1016/j.humpath.2009.11.016.Peer-Reviewed Original ResearchConceptsMonomorphic posttransplant lymphoproliferative disorderPosttransplant lymphoproliferative disorderBone marrow involvementPolymorphic posttransplant lymphoproliferative disordersDiffuse large B-cell lymphomaLarge B-cell lymphomaMarrow involvementLymphoproliferative disordersB-cell lymphomaSerologic parametersEpstein-Barr virus statusPosttransplant lymphoproliferative disorder patientsDe novo diffuse large B-cell lymphomaNovo diffuse large B-cell lymphomaBone marrow examinationElevated lactate dehydrogenaseBone marrow biopsyHodgkin lymphoma typeDiffuse large B-cell lymphoma casesLarge B-cell lymphoma casesB-cell lymphoma casesSensitive screening toolStaging biopsiesExtranodal involvementMarrow examination
2005
Correlation of the FLIPI score for follicular lymphoma with period of diagnosis and type of treatment
Arcaini L, Colombo N, Passamonti F, Burcheri S, Orlandi E, Brusamolino E, Della Porta M, Rumi E, Montanari F, Pascutto C, Paulli M, Lazzarino M. Correlation of the FLIPI score for follicular lymphoma with period of diagnosis and type of treatment. Leukemia Research 2005, 30: 277-282. PMID: 16112730, DOI: 10.1016/j.leukres.2005.07.006.Peer-Reviewed Original ResearchConceptsFLIPI scorePeriod of diagnosisHigh-risk groupFollicular lymphomaIntermediate riskLower riskRisk groupsMedian OSIPI scorePrognostic categoriesPoor-risk groupSubset of patientsSurvival of patientsTime of diagnosisFollicular lymphoma patientsUse of anthracyclinesDistribution of patientsType of treatmentIndependent seriesIndolent outcomeClinical characteristicsIndolent disorderPrognostic scorePrognostic indexWorse prognosis
2004
Reduced-intensity conditioning regimen with thiotepa and fludarabine followed by allogeneic blood stem cell transplantation in haematological malignancies
Alessandrino EP, Bernasconi P, Colombo AA, Caldera D, Malcovati L, Troletti D, Vanelli L, Varettoni M, Montanari F, Lazzarino M. Reduced-intensity conditioning regimen with thiotepa and fludarabine followed by allogeneic blood stem cell transplantation in haematological malignancies. Bone Marrow Transplantation 2004, 34: 1039-1045. PMID: 15516936, DOI: 10.1038/sj.bmt.1704717.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntineoplastic Combined Chemotherapy ProtocolsBlood TransfusionFemaleGraft SurvivalHematologic NeoplasmsHumansMaleMiddle AgedPeripheral Blood Stem Cell TransplantationRecurrenceRemission InductionSurvival AnalysisThiotepaTransplantation ChimeraTransplantation ConditioningTransplantation, HomologousVidarabineConceptsAllogeneic blood stem cell transplantationPeripheral stem cell transplantBlood stem cell transplantationReduced-intensity conditioning regimenStandard myeloablative regimenTransplant-related mortalityPoor performance statusStem cell transplantStem cell transplantationOverall survival probabilityMyeloablative regimenNonrelapse causesComplete remissionConditioning regimenMild nauseaPreparative regimenAdverse eventsPerformance statusMedian ageRBC transfusionCell transplantCell transplantationHaematological malignanciesSerum amylasePatients